These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31260801)

  • 1. Allogeneic Stem Cell Transplantation after Salvage Inotuzumab Ozogamicin: A Happy Ending?
    Ai J
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):e273-e274. PubMed ID: 31260801
    [No Abstract]   [Full Text] [Related]  

  • 2. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
    Izumi A; Tachibana T; Ando T; Tanaka M; Kanamori H; Nakajima H
    Int J Hematol; 2022 Jan; 115(1):69-76. PubMed ID: 34490598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy.
    Kamitori T; Umeda K; Akazawa R; Iwai A; Obu S; Isobe K; Saida S; Kato I; Hiramatsu H; Taga T; Adachi S; Takita J
    Pediatr Blood Cancer; 2021 May; 68(5):e28980. PubMed ID: 33619887
    [No Abstract]   [Full Text] [Related]  

  • 4. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
    Papayannidis C; Sartor C; Dominietto A; Zappone E; Arpinati M; Marconi G; Cristiano G; Nanni J; Parisi S; Barbato F; Paolini S; Soverini S; Terragna C; Robustelli V; Testoni N; Chirumbolo G; Curti A; Cavo M; Bonifazi F
    Hematol Oncol; 2021 Oct; 39(4):580-583. PubMed ID: 33963566
    [No Abstract]   [Full Text] [Related]  

  • 5. [Allogeneic hematopoietic stem cell transplantations for relapsed and refractory acute lymphoblastic leukemia following inotuzumab ozogamicin treatment].
    Morishige S; Yamasaki Y; Oya S; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Mizushima Y; Nakashima O; Nagafuji K
    Rinsho Ketsueki; 2022; 63(4):271-276. PubMed ID: 35491216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Salvage of Very Early Relapse in Pediatric Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin and HLA-haploidentical Peripheral Blood Stem Cell Transplantation With Posttransplant Cyclophosphamide.
    Abematsu T; Nishikawa T; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):62-64. PubMed ID: 33512872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and
    Kayser S; Sartor C; Luskin MR; Webster J; Giglio F; Panitz N; Brunner AM; Fante M; Lutz C; Wolff D; Ho AD; Levis MJ; Schlenk RF; Papayannidis C
    Haematologica; 2022 Sep; 107(9):2064-2071. PubMed ID: 35142153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.
    Jabbour E; Stelljes M; Advani AS; DeAngelo DJ; Gökbuget N; Marks DI; Stock W; O'Brien S; Cassaday RD; Wang T; Neuhof A; Vandendries E; Kantarjian H
    Leuk Lymphoma; 2020 Aug; 61(8):2012-2015. PubMed ID: 32378440
    [No Abstract]   [Full Text] [Related]  

  • 9. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
    McDonald GB; Freston JW; Boyer JL; DeLeve LD
    Hepatology; 2019 Feb; 69(2):831-844. PubMed ID: 30120894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.
    Okura M; Ida N; Yamauchi T
    Intern Med; 2020 Aug; 59(16):2047-2051. PubMed ID: 32389945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
    Al-Salama ZT
    Target Oncol; 2018 Aug; 13(4):525-532. PubMed ID: 30090971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
    Cassaday RD; Marks DI; DeAngelo DJ; Jabbour EJ; Advani AS; O'Brien S; Wang T; Neuhof A; Vandendries E; Kantarjian HM; Stock W; Stelljes M
    Br J Haematol; 2020 Nov; 191(3):e77-e81. PubMed ID: 32805058
    [No Abstract]   [Full Text] [Related]  

  • 15. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotuzumab ozogamicin in acute lymphoblastic leukaemia.
    Gourd E
    Lancet Oncol; 2019 May; 20(5):e248. PubMed ID: 30956118
    [No Abstract]   [Full Text] [Related]  

  • 17. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A; O'Brien SM
    Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.
    Thomas X
    Expert Opin Investig Drugs; 2012 Jun; 21(6):871-8. PubMed ID: 22500551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Vandendries E; Pagé V; Cappelleri JC; Stelljes M
    Adv Ther; 2020 Feb; 37(2):958-962. PubMed ID: 31838711
    [No Abstract]   [Full Text] [Related]  

  • 20. Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia.
    Tinajero J; Koller P; Ali H
    Leuk Res; 2023 Jun; 129():107299. PubMed ID: 37120933
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.